Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
17877 | 515 | 41.7 | 22% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1294 | 8163 | FOOD AND DRUG LAW JOURNAL//GENERIC SUBSTITUTION//DIRECT TO CONSUMER ADVERTISING |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | COMPULSORY LICENSING | Author keyword | 5 | 42% | 2% | 10 |
2 | ACCESS TO MEDICINES | Author keyword | 5 | 29% | 3% | 15 |
3 | DOHA DECLARATION | Author keyword | 5 | 63% | 1% | 5 |
4 | COMPARAT PROGRAM HLTH SOC | Address | 3 | 57% | 1% | 4 |
5 | TRIPS | Author keyword | 2 | 13% | 3% | 18 |
6 | ACCESS TO ESSENTIAL MEDICINES | Author keyword | 2 | 67% | 0% | 2 |
7 | ANTI HIV AGENTS ECONOMICS | Author keyword | 2 | 67% | 0% | 2 |
8 | TRIPS AGREEMENT | Author keyword | 2 | 20% | 2% | 10 |
9 | NEPAIDS | Address | 2 | 50% | 1% | 3 |
10 | ACIPA | Address | 1 | 50% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TRIPS AGREEMENT | 5 | 54% | 1% | 7 |
2 | AIDS TREATMENT | 2 | 29% | 1% | 5 |
3 | ANTIRETROVIRAL MEDICINES | 1 | 100% | 0% | 2 |
4 | UNIVERSAL ACCESS | 1 | 15% | 1% | 7 |
5 | DOHA DECLARATION | 1 | 40% | 0% | 2 |
6 | PROTEST PARADIGM | 1 | 50% | 0% | 1 |
7 | REDUCE CARDIOVASCULAR DISEASE | 1 | 50% | 0% | 1 |
8 | TRADE CONSTITUTION | 1 | 50% | 0% | 1 |
9 | TRIPS PLUS | 1 | 50% | 0% | 1 |
10 | ESSENTIAL MEDICINES | 1 | 11% | 1% | 6 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Access to medications and conducting clinical trials in LMICs | 2015 | 1 | 9 | 33% |
Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options | 2009 | 12 | 9 | 89% |
Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: high, low or just right? | 2014 | 1 | 2 | 100% |
Antiretroviral procurement and supply chain management | 2014 | 1 | 2 | 100% |
Regulatory framework for access to safe, effective quality medicines | 2014 | 2 | 3 | 67% |
The role of intellectual property rights in treatment access: challenges and solutions | 2013 | 1 | 12 | 92% |
Production of antiretroviral drugs in middle- and low-income countries | 2014 | 2 | 2 | 50% |
Intellectual property rights, market competition and access to affordable antiretrovirals | 2014 | 2 | 10 | 50% |
Basic Survival Needs and Access to Medicines - Coming to Grips with TRIPS: Conversion plus Calculation | 2010 | 6 | 8 | 63% |
Driving a decade of change: HIV/AIDS, patents and access to medicines for all | 2011 | 4 | 23 | 48% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | COMPARAT PROGRAM HLTH SOC | 3 | 57% | 0.8% | 4 |
2 | NEPAIDS | 2 | 50% | 0.6% | 3 |
3 | ACIPA | 1 | 50% | 0.4% | 2 |
4 | GLOBAL IP ISSUES | 1 | 100% | 0.4% | 2 |
5 | PROGRAM HUMAN RIGHTS GLOBAL ECON | 1 | 50% | 0.4% | 2 |
6 | SEPN 510 | 1 | 100% | 0.4% | 2 |
7 | WHO ABORATING PHARMACEUT POLICIES | 1 | 100% | 0.4% | 2 |
8 | GLOBAL HLTH AFFAIRS PROGRAM | 1 | 33% | 0.4% | 2 |
9 | SERGIO AROUCA PUBL HLTH | 1 | 16% | 0.8% | 4 |
10 | AIDS REFERENCE TRAINING | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000204511 | PHARMACEUTICAL ASSISTANCE//JUDICIAL DECISIONS//NATIONAL POLICY OF PHARMACEUTICAL ASSISTANCE |
2 | 0.0000156608 | HLTH STUDIES AREA//PAYSON INT DEV TECHNOL TRANSFER//BIOTECHNOL FDN |
3 | 0.0000147210 | AIDS DENIALISM//TREATMENT ACTION CAMPAIGN//COMPANY PROGRAMMES |
4 | 0.0000145575 | JOURNAL OF THE PATENT OFFICE SOCIETY//IIC-INTERNATIONAL REVIEW OF INDUSTRIAL PROPERTY AND COPYRIGHT LAW//NON DISCRIMINATION PRINCIPLE |
5 | 0.0000127528 | GENERIC SUBSTITUTION//GENERIC DRUGS//REFERENCE PRICING |
6 | 0.0000119447 | DEVELOPMENT OF SOCIETIES//INDIGENOUS ACCREDITATION//MT ROMANCE |
7 | 0.0000105608 | GLOBAL HEALTH INITIATIVES//GLOBAL FUND//GLOBAL HEALTH GOVERNANCE |
8 | 0.0000105481 | ESCUELA NACL SALUD PUBL//CHRON DIS WELL BEING//FEMINIST SCIENCE AND TECHNOLOGY STUDIES |
9 | 0.0000086814 | ORPHAN DRUGS//RARE DISEASES//OFF ORPHAN PROD DEV |
10 | 0.0000086364 | JOURNAL OF INTERNATIONAL ECONOMIC LAW//JOURNAL OF WORLD TRADE//WORLD TRADE REVIEW |